BeyondSpring

BeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. It operates through the PRC and U.S. geographical segments. The company was founded by Lan Huang and Lin Qing Jia in 2010 and is headquartered in New York, NY.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. It operates through the Plinabulin Pipeline and TPD Platform segments. The Plinabulin Pipeline segment focuses on the development of cancer therapies. The TPD Platform segment engages in the development of therapeutic agents and discover chemical entities. The company was founded by Lan Huang and Lin Qing Jia in 2010 and is headquartered in Florham Park, NJ.

Webinar on Thursday, March 18 th @ 10:00 a.m. ET

BeyondSpring Hosting Key Opinion Leader Webinar on Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia

NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that CEO Dr. Lan Huang is scheduled to present virtually at the 39th Annual J.P. Morgan Healthcare Conference (JPM) on Thursday, January 14, 2021 at 7:30 a.m. ET, and will be available for 1x1 meetings. The BeyondSpring leadership team also will be available for one-on-one meetings during the LifeSci Advisors Corporate Access Event on January 7-8 and 11-13, 2021.

UPDATE -- BeyondSpring to Present at the J.P. Morgan Healthcare Conference on January 14, 2021

BeyondSpring to Present at the J.P. Morgan Healthcare Conference on January 14, 2021

NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Jeffrey Vacirca to its Board of Directors to help guide the company as it seeks commercial approval following announcement of positive Phase 3 data from the PROTECTIVE-2 study of plinabulin in combination with pegfilgrastim for protection against chemotherapy-induced neutropenia.

BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors

BYSI's lead candidate plinabulin in combo with Neulasta reduces grade 4 neutropenia in chemo patients better than Neulasta alone.

BeyondSpring: Would Be A Great Buy Except For The Perennial Need For Cash And Ensuing Dilution

- The plinabulin + pegfilgrastim combination reduces the incidence of profound neutropenia (ANC < 0.1 x 10E9 cells/L) by 53 % vs. pegfilgrastim alone

BeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results at the 2020 San Antonio Breast Cancer Symposium

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of capital and have to conduct due diligence while choosing their next pick. They don't always get it right, but, on average, their stock picks historically generated strong returns after adjusting for known risk factors. With this in mind, let's take a look at the recent hedge fund activity surrounding BeyondSpring, Inc. (NASDAQ:BYSI).

Do Hedge Funds Love BeyondSpring, Inc. (BYSI)?

NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced a poster presentation about the PROTECTIVE-2 Trial (ClinicalTrials.gov ID: NCT03294577) at the 62nd American Society of Hematology (ASH) Annual Meeting being held virtually December 5-8, 2020. The Company will also present three posters about the PROTECTIVE-1 Trial and PROTECTIVE-2 Trial at the San Antonio Breast Cancer Symposium (SABCS) being held virtually December 8-11, 2020.

BeyondSpring to Present at Two Upcoming Scientific Conferences in December

NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to transform the lives of patients with unmet medical needs, today announced that management will provide a corporate overview at the 2020 Evercore ISI HealthCONx Conference on December 2, 2020.

BeyondSpring to Participate in Upcoming Evercore ISI 2020 Conference

NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the pricing of its public offering of 7,500,000 ordinary shares at a public offering price of $10.00 per share. The gross proceeds from the public offering are expected to be approximately $75.0 million, before deducting underwriting discounts and commissions and other offering expenses. The underwriters have a 30-day option to purchase from the Company up to an additional 1,125,000 ordinary shares at the public offering price, less underwriting discounts and commissions. The Company intends to use the net proceeds of this offering to support the commercialization of plinabulin, continued clinical and pre-clinical development and for general corporate purposes. The offering is expected to close on November 23, 2020, subject to satisfaction of customary closing conditions.

BeyondSpring Announces Pricing of Ordinary Shares

NEW YORK, Nov. 17, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the launch of an underwritten public offering of $75 million of its ordinary shares. The Company also expects to grant the underwriters an option to purchase up to an additional $11.25 million of the ordinary shares being offered. The Company intends to use the net proceeds of this offering to support the commercialization of Plinabulin, continued clinical and pre-clinical development and for general corporate purposes.

BeyondSpring Announces Proposed Public Offering of Ordinary Shares

- Announced SEED Therapeutics Inc.(“SEED”)'s collaboration with Eli Lilly and Company(“Lilly”)

BeyondSpring Announces Third Quarter 2020 Financial Results and Provides Business Updates

NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to transform the lives of patients with unmet medical needs, today announced that management will provide a corporate overview at the Jefferies London Healthcare Conference on November 17th. Details are as follows:

BeyondSpring to Present Corporate Overview at Jefferies London Healthcare Conference

- Seed Therapeutics to Use Proprietary “Molecular Glue” Protein Degradation Technology to Develop Potential New Medicines -

BeyondSpring Subsidiary, Seed Therapeutics, Announces Research Collaboration and License Agreement with Lilly

Former Forty Seven and Roche Senior Executives to Support Partnering Efforts Former Forty Seven and Roche Senior Executives to Support Partnering Efforts

BeyondSpring Forms Partnership Advisory Committee Comprised of Industry Veterans

NEW YORK, Sept.  29, 2020  (GLOBE NEWSWIRE) --  BeyondSpring Inc.  (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology therapies to transform the lives of patients with unmet medical needs, today announced that the Company’s manuscript, titled “Efficacy of Plinabulin vs. Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non-Small Cell Lung Cancer,” has been published in JAMA Oncology, the American Medical Association’s peer-reviewed journal.

JAMA Oncology Highlights Plinabulin's Efficacy in Preventing Chemotherapy-Induced Neutropenia as a Monotherapy

Poster Presentation at ESMO Congress 2020 Demonstrates Plinabulin’s Early Onset Protection, with a CIN Effect Comparable to Pegfilgrastim, Plus Improved Platelet Counts and Reduced Bone Pain Poster Presentation at ESMO Congress 2020 Demonstrates Plinabulin’s Early Onset Protection, with a CIN Effect Comparable to Pegfilgrastim, Plus Improved Platelet Counts and Reduced Bone Pain

New Data Highlights BeyondSpring’s Plinabulin as a Highly Effective Agent for Preventing Chemotherapy-Induced Neutropenia, with Potential to Reduce Clinical Resources for COVID-19

New Subsidiary Focused on Targeted Protein Degradation, Seed Therapeutics, Appoints Edward Liu as CFO New Subsidiary Focused on Targeted Protein Degradation, Seed Therapeutics, Appoints Edward Liu as CFO

BeyondSpring Appoints Elizabeth Czerepak as Chief Financial Officer

NEW YORK, Sept.  11, 2020  (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to transform the lives of patients with unmet medical needs, today announced that management will provide a corporate overview at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference on Monday, September 14, 2020, at 1:00 p.m. Eastern Time.

BeyondSpring to Present at the H.C. Wainwright 22nd Annual Global Investment Conference  on September 14, 2020

BeyondSpring (BYSI) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

BeyondSpring (BYSI) Looks Good: Stock Adds 5.1% in Session

- FDA Breakthrough Designation for CIN Indication: Plinabulin for Concurrent Administration with Myelosuppressive Chemotherapeutic Regimens in Patients with Non-Myeloid Malignancies for the Prevention of Chemotherapy-Induced Neutropenia (CIN) -

BeyondSpring Receives Breakthrough Therapy Designations from Both U.S. FDA and China NMPA for Plinabulin in Chemotherapy-Induced Neutropenia Indication

BeyondSpring Inc. (BYSI) CEO Lan Huang on Q2 2020 Results - Earnings Call Transcript

NEW YORK, Aug.  27, 2020  (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company will report its second-quarter 2020 financial results and host an operational update conference call on Thursday, September 3rd, 2020, at 8 a.m. Eastern Time.

BeyondSpring to Host Second-Quarter 2020 Financial Results and Operational Update Conference Call on September 3rd, 2020

G1 Therapeutics

Karyopharm Therapeutics

UroGen Pharma

Oncology Stocks Area Trading Materially Lower The Last 2 Months

Of a pool of 26 oncology stocks we track, with 1 exception, all (literally 25 of 26) are trading materially lower from the third week of June 2020.

News for BeyondSpring Stock (BYSI)